1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow MLN2238: new trials by email Literature Review of MLN2238 trials Research Report on MLN2238
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma Ixazomib, Ixazomib Citrate, Rituximab - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2019-08-28 | 2025-04-20 |
M.D. Anderson Cancer Center (1)
United States (1)
Hun J Lee (1)